UA102432C2 - Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y - Google Patents

Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y

Info

Publication number
UA102432C2
UA102432C2 UAA201111162A UAA201111162A UA102432C2 UA 102432 C2 UA102432 C2 UA 102432C2 UA A201111162 A UAA201111162 A UA A201111162A UA A201111162 A UAA201111162 A UA A201111162A UA 102432 C2 UA102432 C2 UA 102432C2
Authority
UA
Ukraine
Prior art keywords
neuropeptide
cytotoxic conjugates
conjugates
cytotoxic
aberrant
Prior art date
Application number
UAA201111162A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чжен Сінь Дун
Кевін Л. Чжоу
Деніел Б. Деолівейра
Original Assignee
Іпсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Іпсен Фарма С.А.С. filed Critical Іпсен Фарма С.А.С.
Publication of UA102432C2 publication Critical patent/UA102432C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Изобретение касается групп новых конъюгатов нейропептида Y и цитотоксических соединений, композиций, которые их содержат, и способов их терапевтического применения для лечения заболевания или состояния, ассоциированного с нарушенной или нежелательной пролиферацией клеток, которые экспрессируют рецепторы NPY-Y1.
UAA201111162A 2009-02-20 2010-02-19 Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y UA102432C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20815409P 2009-02-20 2009-02-20
PCT/US2010/000473 WO2010096175A1 (en) 2009-02-20 2010-02-19 Cytotoxic conjugates having neuropeptide y receptor binding compound

Publications (1)

Publication Number Publication Date
UA102432C2 true UA102432C2 (ru) 2013-07-10

Family

ID=42634162

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201111162A UA102432C2 (ru) 2009-02-20 2010-02-19 Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y

Country Status (12)

Country Link
US (1) US8877715B2 (ru)
EP (1) EP2398492A4 (ru)
JP (1) JP5584236B2 (ru)
KR (1) KR101413051B1 (ru)
CN (1) CN102325545A (ru)
AU (1) AU2010216372B2 (ru)
BR (1) BRPI1008039A2 (ru)
CA (1) CA2752608A1 (ru)
EA (1) EA020613B1 (ru)
MX (1) MX2011008774A (ru)
UA (1) UA102432C2 (ru)
WO (1) WO2010096175A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925620B1 (ko) 2010-12-16 2018-12-05 노보 노르디스크 에이/에스 Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
EP2708243A1 (en) * 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
CN104768565B (zh) * 2012-11-01 2017-04-26 益普生制药股份有限公司 促生长素抑制素类似物及其二聚体
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
EP3068421B1 (en) 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
AR104984A1 (es) 2015-06-12 2017-08-30 Novo Nordisk As Compuestos selectivos para pyy y sus usos
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017156183A1 (en) * 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
CN106279287B (zh) * 2016-08-12 2018-11-30 华中科技大学 一种喜树碱磷酸酯类化合物、其制备方法及应用
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
DK3774838T3 (da) * 2018-04-10 2022-10-31 Sanofi Aventis Deutschland Lixisenatidsyntese med capping
EP4003403A1 (en) * 2019-07-24 2022-06-01 Molgenie GmbH Receptor-targeting peptide-drug conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7174494A (en) * 1993-06-18 1995-01-17 University Of Cincinnati, The Neuropeptide y antagonists and agonists
US20030022277A1 (en) * 1995-05-05 2003-01-30 Daniel R. Soppet Human neuropeptide receptor
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
ATE368476T1 (de) * 2000-11-24 2007-08-15 Jean-Claude Reubi Neuropeptid-y1-rezeptor-bindende verbindungen zur behandlung und diagnose von krebserkrankungen
WO2007039318A2 (en) * 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Neuropeptide y analogs
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
MX2009004178A (es) * 2006-10-20 2009-09-07 Ipsen Pharma Sas Conjugados peptidicos citotoxicos.
EP2609934A1 (en) * 2007-02-16 2013-07-03 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
US8440611B2 (en) * 2009-02-20 2013-05-14 Ipsen Pharma S.A.S. Analogues of neuropeptide Y having at least one synthetic amino acid substitution

Also Published As

Publication number Publication date
EP2398492A4 (en) 2013-07-17
AU2010216372A1 (en) 2011-09-15
CN102325545A (zh) 2012-01-18
JP5584236B2 (ja) 2014-09-03
US20120010154A1 (en) 2012-01-12
CA2752608A1 (en) 2010-08-26
WO2010096175A1 (en) 2010-08-26
EA201171074A1 (ru) 2012-04-30
MX2011008774A (es) 2011-10-24
KR101413051B1 (ko) 2014-07-31
US8877715B2 (en) 2014-11-04
AU2010216372B2 (en) 2013-06-20
JP2012518636A (ja) 2012-08-16
EA020613B1 (ru) 2014-12-30
BRPI1008039A2 (pt) 2016-10-04
KR20110125235A (ko) 2011-11-18
EP2398492A1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
IN2012DN00624A (ru)
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
NZ597517A (en) 5-fluoropyrimidinone derivatives
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
GB0920703D0 (en) Compositions containing satiogens and methods of use
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
MX2011007930A (es) Conjugados de insulina cristalina.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EA020330B3 (ru) Хиназолиновые соединения
UY31228A1 (es) Ariloxazoles sustituidos y su uso
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IN2012DN02471A (ru)
MY186456A (en) Quinazoline carboxamide azetidines
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX342947B (es) Tratamiento de diabetes tipo 2.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MY150931A (en) Substituted oxazolidinones and their use
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.